Law firm Eversheds has advised Recordati Spa, a major Italian group of pharmaceutical laboratories, on the acquisition of 67% of shares in Tunisian pharmaceutical company Opalia Pharma. Milan-based Recordati is a specialty pharmaceutical group with a global reach. Opalia Pharma S.A. is a Tunisian pharmaceutical company that markets branded generic drugs with leading products in dermatology and in the gastro-intestinal and respiratory therapeutic areas. Recordati was advised Eversheds Paris in collaboration with Eversheds El Heni in Tunisia, with partners Boris Martor, Farès Koussay El Heni, Raouf Mohamed El Heni and Dan Roskis, working closely with associates Jawad Fassi-Fehri and Imène Boukadoum. Further counsel was provided by Anna Buscall of Arnold & Porter.